Rebecca S. Bahn - Böcker

This title is an addition to the Endocrine Updates series. The aim of these publications is to provide the clinician with cutting edge, yet succint, access to the latest advances in endocrinology. Dr. Bahn and her colleagues present exciting developments. These investigators are increasing the quality of life for thyroid eye disease patients. "Thyroid Eye Disease" continues the standard of excellence as the 14th volume in this series of topical updates. Full patients afflicted with thyroid eye disease or Graves' ophthamopathy (GO) may experience not only pain and visual loss, but also disfigurement. Understanding of pathogenesis has been elusive, and treatment modalities are imperfect. As with other conditions, more effective intervention will follow only after a better understanding of pathogenesis is reached. The goal of this volume is to give an overview by leaders in the field of the present state of the art both in pathogenesis and clinical aspects of GO.

Also to be decided is whether orbital lymphocytes from GO patients specifically recognize this receptor, and what factor or factors unique to Graves' dIsease might stimulate TSHr expression in orbital cells.

This indispensable volume is designed to facilitate the best possible physician–patient discussion on Graves’ disease by providing the most up-to-date evidence-based information in a clinically useful and patient-centric manner. Comprehensive and covering such topics as Professionalism and the Art of Patient-centric Thyroidology, the Immunopathogenesis of Graves’ Disease, and the Diagnosis and Management of Thyroid Storm, the book addresses all the important refinements in the treatment of Graves’ disease in recent years. These include new indications and contraindications for antithyroid drugs, improved approaches to radioactive iodine therapy, the development of novel surgical techniques, and a better understanding of the combined use of these modalities, among other developments. Also addressed are the advances in the treatment of GO, including the use of disease activity and severity assessments to inform management decisions and the completion of the first randomized controlled therapeutic trials. Developed by a renowned group of internationally respected authorities, Graves’ Disease: A Comprehensive Guide for Clinicians is a significant new reference that will be of great interest to all clinicians who treat this debilitating condition.